Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:06 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 17,839 matching trials from the live ClinicalTrials.gov search.
Conditions
Chemotherapy-induced Diarrhea
Interventions
SK10, Placebo
Drug
Lead sponsor
Guangzhou Zhiyi Biotechnology Co., Ltd.
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Glendale, California
Conditions
Renal Failure, Tremors
Interventions
Prograf, LCP-Tacro
Drug
Lead sponsor
Asahi Kasei Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Conditions
Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
Interventions
THR-687 dose level 1, THR-687 dose level 2, THR-687 dose level 3
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Winter Haven, Florida • Indianapolis, Indiana + 4 more
Conditions
Prostatic Neoplasms
Interventions
Radiotherapy, LHRHa, Apalutamide
Radiation · Drug
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Industry
Eligibility
18 Years and older · Male only
Enrollment
691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
13
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 10 more
Conditions
White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia, Periventricular White Matter Abnormalities
Interventions
Clemastine fumarate
Drug
Lead sponsor
Bridget LaMonica Ostrem, M.D., Ph.D.
Other
Eligibility
3 Weeks to 20 Weeks
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Conditions
Influenza, Human
Interventions
mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
12
States / cities
Glendale, Arizona • Tucson, Arizona • San Diego, California + 9 more
Conditions
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
Interventions
erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Houston, Texas
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Glendale, Arizona • San Jose, California + 18 more
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Ulcerative Colitis
Interventions
Visilizumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Savannah, Georgia • Worcester, Massachusetts • Manhasset, New York + 2 more
Conditions
Lymphoma
Interventions
milatuzumab, veltuzumab, Correlative/Special Studies, Quantitative T-, B-, and NK cell subsets, Pharmacokinetics, Human Anti-Human Antibodies, veltuzumab and milatuzumab
Biological · Procedure
Lead sponsor
Beth Christian
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Interventions
AMO959, AAA617, Enzalutamide, Abiraterone
Drug · Radiation
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
Los Angeles, California • Durham, North Carolina • El Paso, Texas + 1 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Spinal Cord Injury Cervical
Interventions
Active Stimulation, Sham, Training only
Other
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Orange, New Jersey
Active, not recruiting Phase 1Phase 2 Interventional

Promising ROd-cone DYstrophy Gene therapY

NCT05748873
Conditions
Retinitis Pigmentosa
Interventions
SPVN06
Drug
Lead sponsor
SparingVision
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Portland, Oregon + 2 more
Conditions
Stage IV Non-Small Cell Lung Cancer
Interventions
Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy)
Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE

NCT03170869
Conditions
Hepatocellular Carcinoma of the Liver, Subjects Eligible for Liver Transplantation
Interventions
Surefire Precision Infusion System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Lipedema, Dercum Disease
Interventions
RZL-012
Drug
Lead sponsor
Raziel Therapeutics Ltd.
Industry
Eligibility
20 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Hodgkin's Lymphoma, Leukemia, Myelodysplastic Syndrome(MDS), Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions
Cyclophosphamide, Fludarabine, Total body irradiation, Mycophenolate Mofetil, Tacrolimus 60, Tacrolimus 90, Tacrolimus 120, Bone marrow transplant
Drug · Radiation · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Savella in Treatment for Provoked Vestibulodynia

NCT01304589
Conditions
Vestibulodynia, Vulvodynia
Interventions
Milnacipran
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Germantown, Tennessee
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
Conditions
Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
Interventions
IMM2902
Drug
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • Dallas, Texas • Fairfax, Virginia
Conditions
Lymphoma
Interventions
Regimen A, Regimen B
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
8
States / cities
Chicago, Illinois • Maywood, Illinois • Park Ridge, Illinois + 3 more
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Interventions
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Revlimid (lenalidomide)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland